BIOMAT Database Logo BIOMAT Database Logo

Effect of BCG immunotherapy on cell-mediated cytotoxicity in bladder cancer patients following surgical treatment. 1981

S Antonaci, and A Piccinno, and G Lucivero, and A Miglietta, and A Piccininno, and L Bonomo

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011948 Receptors, Antigen, T-Cell Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains. Antigen Receptors, T-Cell,T-Cell Receptors,Receptors, T-Cell Antigen,T-Cell Antigen Receptor,T-Cell Receptor,Antigen Receptor, T-Cell,Antigen Receptors, T Cell,Receptor, T-Cell,Receptor, T-Cell Antigen,Receptors, T Cell Antigen,Receptors, T-Cell,T Cell Antigen Receptor,T Cell Receptor,T Cell Receptors,T-Cell Antigen Receptors
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D005260 Female Females

Related Publications

S Antonaci, and A Piccinno, and G Lucivero, and A Miglietta, and A Piccininno, and L Bonomo
[BCG infection following intravesicular immunotherapy for bladder cancer].
April 2018, Revue des maladies respiratoires,
S Antonaci, and A Piccinno, and G Lucivero, and A Miglietta, and A Piccininno, and L Bonomo
BCG in Bladder Cancer Immunotherapy.
June 2022, Cancers,
S Antonaci, and A Piccinno, and G Lucivero, and A Miglietta, and A Piccininno, and L Bonomo
Response to: BCG infection following immunotherapy for bladder cancer.
March 2020, QJM : monthly journal of the Association of Physicians,
S Antonaci, and A Piccinno, and G Lucivero, and A Miglietta, and A Piccininno, and L Bonomo
Bladder contracture following intravesical BCG immunotherapy.
April 1993, Urology,
S Antonaci, and A Piccinno, and G Lucivero, and A Miglietta, and A Piccininno, and L Bonomo
[ BCG-immunotherapy and bladder cancer].
May 2008, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie,
S Antonaci, and A Piccinno, and G Lucivero, and A Miglietta, and A Piccininno, and L Bonomo
BCG immunotherapy of bladder cancer: 20 years on.
May 1999, Lancet (London, England),
S Antonaci, and A Piccinno, and G Lucivero, and A Miglietta, and A Piccininno, and L Bonomo
[Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].
May 2006, Der Urologe. Ausg. A,
S Antonaci, and A Piccinno, and G Lucivero, and A Miglietta, and A Piccininno, and L Bonomo
[Granulomatous hepatitis following intravesical BCG immunotherapy for cancer of the bladder].
January 1991, Gastroenterologie clinique et biologique,
S Antonaci, and A Piccinno, and G Lucivero, and A Miglietta, and A Piccininno, and L Bonomo
BCG immunotherapy for superficial bladder cancer.
March 2001, Journal of the Royal Society of Medicine,
S Antonaci, and A Piccinno, and G Lucivero, and A Miglietta, and A Piccininno, and L Bonomo
BCG immunotherapy for superficial bladder cancer.
June 2001, Journal of the Royal Society of Medicine,
Copied contents to your clipboard!